Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
USNA Transcript
USANA Health Sciences, Inc. (USNA) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call reveals strong financial performance with a 7% growth in core nutritional net sales and a significant increase in Rise Wellness sales. The company is expanding internationally and investing in technology modernization, which could enhance future performance. However, risks such as economic uncertainty and high customer acquisition costs for Hiya are noted. Positive elements include expected margin efficiencies, retail expansion, and a stable macro environment in China. The lack of guidance on new product launches was a minor negative, but overall, the sentiment is positive, anticipating a stock price increase of 2% to 8%.
USANA Health Sciences, Inc. (USNA) Q4 2025 Earnings Call Transcript
Unknown2-18
The earnings call reveals mixed signals: strong growth in Hiya and Rise Wellness, but challenges with high tax rates and core business sales decline. The Q&A session highlights growth potential in new markets but lacks detailed insights, creating uncertainty. While the company's strategic initiatives and expansion plans are promising, concerns about profitability and financial uncertainty persist. Consequently, a neutral stock price movement is anticipated over the next two weeks, as positive growth prospects are balanced by financial and operational risks.
USANA Health Sciences, Inc. (USNA) Q3 2025 Earnings Call Transcript
Unknown10-23
The earnings call highlights mixed signals: positive sales growth for Hiya and Rise Bar, promising trends from the new compensation plan, and strategic incentives planned for Q4. However, challenges include short-term margin pressures, potential operational disruptions from cost reductions, and uncertainties in supply chain transitions. The Q&A reveals management's confidence in growth, but lacks specifics on cost savings and Hiya's margin impact. Without clear guidance, the market may react cautiously, leading to a neutral stock price movement prediction.
USANA Health Sciences, Inc. (USNA) Q2 2025 Earnings Call Transcript
Positive7-23
The earnings call reveals strong financial performance, with debt repayment, robust growth in Hiya and Rise Bar, and a new partnership with Disney. The Q&A section addresses concerns about customer decline and tariffs, with management expressing optimism for future growth. The new incentive program and potential share buybacks are positive indicators. Despite some uncertainties, the overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
USNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
